Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. May 24, 2024; 15(5): 635-643
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.635
Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer
Xiao-Ting Ma, Kai Ou, Wen-Wei Yang, Bi-Yang Cao, Lin Yang
Xiao-Ting Ma, Kai Ou, Wen-Wei Yang, Bi-Yang Cao, Lin Yang, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Author contributions: Ma XT designed the article form and wrote the manuscript; Ou K, Yang WW and Cao BY consulted and browsed the literature; Yang L revised the manuscript and provided the funding. All authors read and approved the final manuscript.
Supported by Beijing CSCO Clinical Oncology Research Foundation, No. Y-HH202102-0314.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.
Informed consent statement: As the study used anonymous and pre-existing data, the requirement for the informed consent from patients was waived.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lin Yang, MD, Director, Doctor, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. linyangcicams@126.com
Received: January 2, 2024
Revised: February 8, 2024
Accepted: April 2, 2024
Published online: May 24, 2024
Core Tip

Core Tip: For when considering non-positive human epidermal growth factor receptor 2 (HER2) advanced gastric cancer (AGC), combined positive score and HER2 expression are represent influencing factors for the treatment efficacy of AGC patients receiving immunotherapy combined with chemotherapy. Survival analysis with When using progression-free survival (PFS) as the end point, survival analysis suggested that the HER2 expression level was levels are suggestive of the efficacy of treatment featuring a programmed cell death protein 1 inhibitor combined with and chemotherapy. With the increase of HER2 expression, PFS also showed a tendency to prolong increase with an increase in HER2 expression.